What question did this study set out to answer?

This review aims to integrate recent advances in the management of pediatric low-grade gliomas while highlighting molecular characterization.

June 27, 2026NeurotherapeuticsOpen Access

Advances in the management of pediatric low-grade glioma

View Full Paper

Ask AI

Bookmark

Authors

Review synthesizes emerging therapies and diagnostic advancements in pediatric low-grade gliomas, suggesting improved outcomes.

This review aims to integrate recent advances in the management of pediatric low-grade gliomas while highlighting molecular characterization.
Synthesized recent literature on pLGG management
Reviewed systemic therapies and emerging diagnostic technologies
Discussed integration of molecular classification and targeted therapies
Most pediatric low-grade gliomas are driven by alterations in the RAS/MAPK pathway.
Targeted therapies such as BRAF inhibitors have reshaped treatment paradigms for selected patients.
Emerging technologies like liquid biopsy and AI-enhanced imaging provide new opportunities for diagnosis and surveillance.

Brizini et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark